Aim: Severe mental illnesses (SMI), such as bipolar disorder and schizophrenia, are highly heritable, and have a complex pattern of inheritance. Genome-wide association studies detect a part of the heritability, which can be attributed to common genetic variation. Examination of rare variants with next-generation sequencing may add to the understanding of the genetic architecture of SMI.
A cross-nosology approach has been quite informative in identifying potential disease-relevant pathways in SCZ and BD. 17, 18 Singlenucleotide polymorphisms (SNP) associated with these two syndromes show a high mutual correlation, among combinations of neuropsychiatric syndromes. 7 Such overlaps have also been observed across diverse neuropsychiatric syndromes, for both common and rare genetic variations, as well as in gene expression profiles in the cerebral cortex. 19, 20 These findings indicate an underlying shared molecular pathology in the pathobiology of SMI.
As part of a longitudinal study, 'Accelerator Program for Discovery of Brain Disorders Using Stem Cells' (ADBS), 21 aimed at understanding the developmental trajectories and basic biology of SMI, we describe in this study the results of a variant discovery analysis using whole-exome sequencing (WES) in eight multiplex pedigrees with SCZ and BD phenotypes from a well characterized Indian cohort. Such studies have been predominantly conducted in large cohorts of European origin, 16 and representation from other populations is perhaps necessary to validate earlier findings, and identify populationspecific signatures underlying SMI. In the current study, we aimed to identify rare, damaging, exonic variants that co-segregate with SMI in multiplex families, and to examine their relevance to the disease.
Methods

Sample selection
The families were recruited as part of the ADBS longitudinal study, which has been approved by the ethics committee of the National Institute of Mental Health and Neurosciences, Bengaluru, India. The details of screening, informed consent, recruitment, and phenotyping have been previously published. 21 Some of the families in the cohort have been on follow up for longer than 10 years. We have previously noted evidence of linkage in psychosis at chromosome 18p11.2, 22 and the sex-specific association to the DISC1 gene using a casecontrol study design 23 in samples taken from this cohort. For the current study, eight families (A through H) with high loading of SMI (SCZ, BD, and psychosis in the context of these eight pedigrees; Fig. 1a, Fig. S1 ) were assessed in detail. From these, 32 individuals ('cases'; 16 females) with SMI were available for blood sampling and were subjected to WES. Two senior psychiatrists evaluated all patients and unaffected relatives independently. Diagnoses were made with the ICD-10 Classification for Mental and Behavioural Disorders and were verified in the longitudinal course of follow ups. From five of the eight families, we could also sample eight unaffected individuals who had crossed the age at risk and are defined as a 'familyspecific control' for the respective pedigree henceforth in this report. An independent set of 25 individuals without a history of SMI were further sampled as population-matched controls. Together this group constituted a total of 33 asymptomatic 'controls.' Exome sequencing and analysis Sequencing was carried out on the Illumina Hiseq NGS platform with libraries prepared using Illumina exome kits. Reads were aligned with reference human genome GRCh37 using the Burrows-Wheeler algorithm tool. 24 Variants were called from realigned BAM files using Varscan2 with the standard criteria (min coverage = 8, MAF ≥ 0.25, and P ≤ 0.001). 25 Standard quality control protocols were employed at sequencing, alignment, and variant calling (Fig.S2) . The resulting variant called files were annotated with ANNOVAR. 26 Pedigree-based analysis All variant segregation analysis was performed at the level of individual pedigrees. To ascertain the degree of variance (between pedigrees) and relatedness within family structures, we generated a dendrogram with hierarchical clustering analysis using an allele-sharing matrix of the exonic variants (Appendix S1).
Variant prioritization
Variants were prioritized if:
1 the variant was found to be shared by all affected individuals within the pedigree while allowing for one missing genotype, a method shown to be useful in an earlier study of familial BD 12 ; 2 the variant fell into any of the following deleterious categoriesthe non-synonymous damaging strict (NSD-S) set predicted to be damaging by five prediction algorithms (SIFT, 27 Polyphen-2 HDIV, 28 Mutation taster 2, 29 Mutation assessor, 30 and LRT
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[Appendix S1]), the Disruptive set predicted to result in protein truncation (splice site, stop gain, or stop loss variants), or the nonsynonymous damaging broad (NSD-B) set predicted to be damaging by one or more of the five prediction algorithms; and 3 the variant was rare <1% in Exome Aggregation Consortium -South Asian sample (ExAC-SAS) 32 and completely absent from a control cohort of 33 individuals from the same gene pool (http:// indexdb.ncbs.res.in).
The above variant prioritization was carried out using an inhouse automated pipeline 'varPrio'. Details of the pipeline and the resulting variant enrichment are summarized in Figure1c. To rule out any false positive calls at the final variant list, a representative set of prioritized variants (n=10) was independently confirmed by Sanger sequencing and we noted a 100% concordance.
Functional annotation
We adapted two approaches for evaluating functional impact to the prioritized variants:
• We reviewed the literature on individual genes identified in the NSD-S and the disruptive set carrying rare variants of highest priority (all five in silico predictors) for prior evidence of disease association in neuropsychiatric phenotype.
• For the NSD-B set carrying rare variants of plausible disease relevance (1-5 in silico predictors), we tested for enrichment of the aggregate list using DAVID functional annotation tool 6.8. 33, 34 To test the enrichment on the categories of biological process, molecular function, protein domain, protein-protein interaction, and tissue expression we selected the sources as -'GOTERM_BP_DIRECT', 'GOTERM_MF_DIRECT', 'INTERPRO', 'KEGG_PATHWAY' and'UP_TISSUE' in this in silico approach. Modified Fisher's exact test with Benjamini-Hochberg correction built-in to this algorithm was used to infer enrichment.
Results
Sample characteristics
Of the 32 cases sequenced in the study, 26 were diagnosed with BD, four with SCZ, and one each with SCZ-like psychosis and schizoaffective disorder. They had been ill for a mean (SD) duration of 23.7 (11.1) years, and the mean (SD) age at onset was 23.1 (7.9) years. In most of the pedigrees, there was heterogeneity in the age of onset, illness severity, global outcomes, and segregation of suicidality and psychosis (in BD) with the primary phenotype. Substance use disorder was a common comorbidity, followed by hypothyroidism, seizure disorder, and dementia (Appendix S2, Table S2 ).
In the analysis of relatedness using the cluster dendrogram, 'cases' and 'controls' formed a single cluster possibly resulting from sharing of a large number of common and/or benign exonic variants. As expected, members from each pedigree clustered together due to the relatively larger magnitude of variant sharing (Fig. 1b , Appendix S1). Control10   F23  A02  A03  A01  G28  G26  G25  G27  C13  C11  C12  C09  C10   D14  D16  D17  E20   E18   B07   A04   B05  B06  B08 Table 2 (a)). Two of these nine variants, one each on the GRM1 gene (chr6:146351218, GRCh37) and NIPBL gene (chr5:37010263, GRCh37), were novel. Pathogenic mutations on the GRM1 gene, coding for metabotropic glutamate receptor 1 (mGluR1) result in autosomal dominant (type 44) (OMIM:617691) and recessive (type 13) (OMIM:614831) forms of spinocerebellar ataxia, both of which are characterized by early age of onset and associated intellectual disability. Missense variants have been identified spanning the entire exome of this gene in individuals and families with SCZ and other neuropsychiatric syndromes. 37 Mutations in the NIPBL gene, coding for Cohesin Loading Factor involved cortical neuronal migration, 38 cause Cornelia de Lange syndrome 1. The novel missense variant identified in the pedigree G (chr5:37010263), segregating with BD would result in substitution of polar amino acid glutamine by a hydrophobic amino acid proline. A non-sense mutation at the same codon (rs797045760) is reported to be pathogenic of Cornelia de Lange syndrome 1 (ClinVarSCV000248215.1).
Ten other genes that harbored prioritized variants have been implicated in neuropsychiatric syndromes. We identified a variant (rs148371256) in the NRG2 gene (Neuregulin 2) that was earlier reported to be associated with gamma band oscillations in SCZ with suggestive genome-wide significance. 39 The encoded protein neuregulin-2 has been shown to be critical for the formation and maturation of GABAergic synapses 40 and its ablation results in dopamine dysregulation. 41 Another novel variant (chr3:122423522, GRCh37) was identified in the PARP14 gene (Poly ADP ribose polymerase 14), and the gene has been implicated in posttraumatic stress disorder (PTSD), major depressive disorder (MDD), and attention deficit hyperactivity disorder (ADHD). 42 We also noted a variant (rs534059912) in the GOLM1 gene (Golgi membrane protein 1), which was earlier reported in sporadic Alzheimer's dementia (AD) to influence the pre-frontal cortical volume. 43 A list of these 10 genes, evidence for disease association, and gene ontology descriptions are presented in Table 2 (b). [44] [45] [46] [47] [48] [49] [50] [51] [52] Of the remaining genes, there were several with a plausible role in the biology of SMI, but not thus far implicated in any disease phenotype. These genes, with the ontology descriptions and plausible biological implications, are provided in Table 2 (c).
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Enrichment of coding variants with plausible functional role in SMI The NSD-B set consisted of 248 variants; of these, except for rs570064523 in the PCSK1 gene, which was identified in cases from two families (G and H), no other overlap at the level of family was noted for the remaining 247 variants (Appendix S2, Table S3 ). In the 'protein domains' category tested using the Interpro database as the source, the term 'epidermal growth factor like domain' showed a nominally significant enrichment with P = 0.0013, BenjaminiHochberg false discovery rate corrected P = 0.073. Twelve genes that were enriched for this domain included the NRG2 and SCUBE3 genes, which were also categorized in the NSD-S set along with the NOTCH1, JAG1 and WIF1 genes, which form critical nodes in the notch signaling pathway implicated in neurodevelopment and embryogenesis (Appendix S2, Table S4 ). 59 There was no statistically significant enrichment in any of the remaining categories tested with this in silico approach.
Discussion
The results of our study highlight the usefulness of WES in multiplex families with SMI to identify rare and novel variants that may contribute to the susceptibility to common polygenic syndromes. Many of these variants prioritized by NSD-S, and presumed to be disruptive, map to genes that have been previously reported in GWAS, candidate gene association, post-mortem expression, or animal model studies of SMI. In addition, consistent with the WES approach, we identify variants in genes hitherto not reported in the context of an SMI, but that could potentially contribute to disease biology.
The segregation of rare and deleterious variants in Mendelian disease genes with a neuropsychiatric phenotype is in keeping with some recent observations. Studies have shown that heterozygous carriers of Mendelian disease mutations are at increased risk for specific common diseases. 60 While Mendelian forms of common, complex traits, such as Alzheimer's disease, hypertension, hypercholesterolemia, and hypertriglyceridemia, have long been attributed to rare causal variants in single genes, population-based GWAS in these traits have often implicated genes that also cause single gene disorders. 60 More recently, using electronic health record data, the diseaserelevant phenotypic burden of rare variants in Mendelian genes, thus far not characterized as 'pathogenic,' has been demonstrated across diverse phenotypes. 61 We explored the clinical significance of nine variants in Mendelian genes in the ClinVar database, a publicly available archive of human phenotype-variation relations. 36 None of these variants was annotated as 'pathogenic' or 'likely pathogenic' in the database for the corresponding Mendelian phenotype. As a corollary, none of the families had any identified or suspected case of a severe neurodevelopmental syndrome. However, the predicted deleteriousness by in silico algorithms, a very low prevalence in the population, physical proximity to known pathogenic mutations, and the reported physiological gene function suggest a plausible role for these variants in the etiology of SMI. The impact of these variants in cellular and/or animal models needs to be examined to validate these observations and to establish their causal role in SMI. Interestingly, an earlier WES study in families with BD also reported variants in genes of monogenic syndromes: holoprosencephaly and progressive myoclonic epilepsy. 13 We detected rare variants in 10 additional genes that have been noted in earlier studies to contribute to the risk for polygenic syndromes, such as SCZ, BD, autism, MDD, ADHD, PTSD, AD, and Parkinson's disease. This finding is congruent with the evolving concept of shared molecular neuropathology across SMI. 19 These, along with other identified genes known to be involved in neurodevelopmental processes (e.g., PLXND1) or known to have manifold higher brain expression (e.g., ANLN, LRRC8B) are potential targets to be examined in future studies of SMI. Lastly, of the 12 genes encoding highly conserved epidermal growth factor-like domains and showing nominally significant enrichment to this domain, many encode for proteins that play critical roles during embryogenesis and neurodevelopment. 59 Certain limitations are to be considered while interpreting the results of this study. The relatively small control set sequenced in our study precluded statistical association testing at the level of a variant or a gene. It has been estimated that rare variant association testing at gene level using case-control samples would require sample sizes greater than 20 000 individuals. 62 As an alternative, we considered the minor allele frequency of the variant in ExAC South Asian samples in the prioritization approach, and many of the identified variants were noted to be extremely rare. Second, although we sampled a nearly equal number of affected persons from each family, the relationships within pedigrees were not uniform, potentially adding heterogeneity to the number of identified variants. Thus, we prioritized variants with complete sharing allowing for one missing genotype. This resulted in identification of some variants that were not fully penetrant. Third, like the previous studies of WES in SCZ and BD, we have relied on in silico predictions to infer the deleteriousness of a variant and have considered those predicted by five algorithms as the primary variants of interest. Supporting this approach, a recent analysis noted that the strength of disease association for a nonsynonymous variant increased with the greater number of deleterious predictions in silico. 63 Fourth, inherent to the prioritization criteria of rarity, deleteriousness and segregation, the NSD-S and disruptive variant set presented above would explain only a part of an individual's liability to disease. The results of this analysis represent the shared familial risk for SMI, private to each pedigree, determined by variants of possible major/moderate effect. Lastly, we have not been able to sample all affected individuals from each multiplex pedigree. Among the unaffected individuals, we have been able to sample one to two representative individuals from five of the pedigrees. Thus, the prioritized variants might represent only a part of the shared genetic risk within each pedigree. Using WES data in multiplex families with SMI, we find evidence that suggests intersections in the molecular pathways leading to the expression of polygenic SMI and Mendelian neuropsychiatric syndromes. The patient-derived neural stem cell lines being developed as part of the program 21 will be useful to explore the functional significance of the identified variants accounting for 'modifier genetic background', 64 and to characterize mechanisms that underlie the observed genotype-phenotype correlates.
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